

Nava Therapeutics to Present Preclinical Data on *In Vivo* CAR-T and Kidney Gene Editing at ASGCT 2026

- *NT-001, a CD19 targeted in vivo CAR-T program based on Nava's liver-sparing LNP platform, results in deep B cell depletion in non-human primates*
- *First in class kidney tropic LNP platform enables efficient, systemic delivery of genetic medicines*

CAMBRIDGE, Mass. & PHILADELPHIA, Pa. – May 4, 2026 – Nava Therapeutics, a biotechnology company developing a new class of genetic medicines through precision RNA delivery, today announced it will present preclinical data from its lead programs at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11–15, 2026, in Boston.

Nava's platform is built on proprietary ionizable lipids, engineered for precise tissue-specific delivery. Preclinical data will be presented on Nava's *in vivo* CAR-T and kidney delivery platforms.

- ***In vivo* CAR-T:** NT-001 is an *in vivo* anti-CD19 CAR-T enabled by a novel ionizable lipid with a differentiated biodistribution profile. NT-001 exhibits best-in-class lymphoid tropism with minimal hepatic accumulation and transfection, exceeding the targeting efficiency of prior-generation *in vivo* CAR-T delivery systems. Preclinical studies demonstrated that NT-001 achieved deep B-cell depletion in the peripheral blood and lymphoid tissues of humanized mice and non-human primates, with transient CAR expression, no observed hepatotoxicity or CRS, and a favorable tolerability profile.
- ***In vivo* kidney delivery:** Nava has developed a novel kidney tropic LNP that has demonstrated >70% transfection of relevant cell types in the kidney with systemic infusion, a first in the field of renal genetic medicines. Evidence of efficient gene editing was detected across multiple kidney compartments and cell types, including proximal tubule cells and podocytes. Validation in non-human primates, supported by spatial transcriptomics, confirms efficient transfection following systemic delivery, highlighting the potential of this platform to support the development of a broad range of genetic medicines for chronic kidney diseases.

Both programs are built on Nava's proprietary delivery technology, which exploits novel chemical space to generate ionizable lipids that achieve precise tissue targeting of previously inaccessible extrahepatic tissues. Through rational design and targeted exploration, Nava has developed proprietary LNPs with enhanced potency, favorable tolerability, and scalable manufacturability, making them the ideal backbone for a new wave of differentiated genetic medicines.

Full abstracts are available on the [ASGCT website](#). The presentation details are listed below.

Abstract Title: *In Vivo* CAR-T Cell Therapy Enabled by a Novel, Highly Selective CD8 Targeted Lipid Nanoparticle
Session Type: Oral
Session Name: LNPs for *in vivo* CAR-T applications
Date and Time: Tuesday, May 12 at 9:30 a.m. ET
Location: MCEC Room 210 ABC (Level 2)



Abstract Title: A Novel Class of Ionizable Lipids Drives Efficient Kidney mRNA Delivery and Gene Editing Following Systemic LNP Administration

Session Type: Oral

Session Name: Genome editing II

Date and Time: Thursday, May 14 at 8:00 a.m. ET

Location: MCEC Room 210 ABC (Level 2)

About Nava Therapeutics

Nava Therapeutics is a biotechnology company developing a new generation of genetic medicines through precision RNA delivery. By combining rational lipid design with high-throughput discovery, Nava has built a proprietary LNP platform capable of selectively targeting cells and tissues beyond the liver.

Business Development contact

bd@navatx.com for partnership, licensing, or collaboration inquiries

General Inquiries contact

For all other inquiries, please reach out to info@navatx.com

